[{"id":"c668d4a7-2db9-4659-a308-7bc585eaa55d","acronym":"","url":"https://clinicaltrials.gov/study/NCT02917083","created_at":"2021-01-18T14:19:13.880Z","updated_at":"2025-02-25T16:44:02.059Z","phase":"Phase 1","brief_title":"CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)","source_id_and_acronym":"NCT02917083","lead_sponsor":"Baylor College of Medicine","biomarkers":" TNFRSF8","pipe":" | ","alterations":" TNFRSF8 positive","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • TT11 • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 05/08/2017","start_date":" 05/08/2017","primary_txt":" Primary completion: 04/01/2026","primary_completion_date":" 04/01/2026","study_txt":" Completion: 02/01/2040","study_completion_date":" 02/01/2040","last_update_posted":"2025-02-05"},{"id":"e7d829bd-de22-4969-85f4-ae3c9695ba2f","acronym":"","url":"https://clinicaltrials.gov/study/NCT06090864","created_at":"2025-02-25T17:02:58.123Z","updated_at":"2025-02-25T17:02:58.123Z","phase":"Phase 1/2","brief_title":"ATLCAR.CD30.CCR4 for CD30+ HL ATLCAR.CD30.CCR4 Cells","source_id_and_acronym":"NCT06090864","lead_sponsor":"UNC Lineberger Comprehensive Cancer Center","biomarkers":" TNFRSF8 • CCR4","pipe":"","alterations":" ","tags":["TNFRSF8 • CCR4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fludarabine IV • TT11 • ATLCAR.CD30.CCR4 cells"],"overall_status":"Recruiting","enrollment":" Enrollment 31","initiation":"Initiation: 04/25/2024","start_date":" 04/25/2024","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 07/01/2031","study_completion_date":" 07/01/2031","last_update_posted":"2025-02-03"},{"id":"1bee75b3-9c2d-44df-aa38-d77483458e28","acronym":"","url":"https://clinicaltrials.gov/study/NCT02690545","created_at":"2021-01-17T17:19:13.271Z","updated_at":"2024-07-02T16:35:08.192Z","phase":"Phase 1/2","brief_title":"Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL","source_id_and_acronym":"NCT02690545","lead_sponsor":"UNC Lineberger Comprehensive Cancer Center","biomarkers":" TNFRSF8","pipe":" | ","alterations":" TNFRSF8 expression","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TT11 • ATLCAR.CD30 cell therapy"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 08/26/2016","start_date":" 08/26/2016","primary_txt":" Primary completion: 08/26/2025","primary_completion_date":" 08/26/2025","study_txt":" Completion: 08/26/2040","study_completion_date":" 08/26/2040","last_update_posted":"2024-04-23"},{"id":"1e1f1982-bd28-4ad1-b264-11dd83d52229","acronym":"","url":"https://clinicaltrials.gov/study/NCT02663297","created_at":"2021-01-18T12:58:42.532Z","updated_at":"2024-07-02T16:35:08.127Z","phase":"Phase 1","brief_title":"Administration of T Lymphocytes for Prevention of Relapse of Lymphomas","source_id_and_acronym":"NCT02663297","lead_sponsor":"UNC Lineberger Comprehensive Cancer Center","biomarkers":" ALK • TNFRSF8","pipe":" | ","alterations":" TNFRSF8 expression • ALK negative • TNFRSF8 negative","tags":["ALK • TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 expression • ALK negative • TNFRSF8 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TT11 • ATLCAR.CD30 cell therapy"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 07/15/2016","start_date":" 07/15/2016","primary_txt":" Primary completion: 01/15/2021","primary_completion_date":" 01/15/2021","study_txt":" Completion: 01/01/2037","study_completion_date":" 01/01/2037","last_update_posted":"2024-04-23"},{"id":"2b050358-3cb8-4957-b9a8-e85ed3d13514","acronym":"","url":"https://clinicaltrials.gov/study/NCT04083495","created_at":"2021-01-18T19:59:38.796Z","updated_at":"2024-07-02T16:35:08.223Z","phase":"Phase 2","brief_title":"CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma","source_id_and_acronym":"NCT04083495","lead_sponsor":"UNC Lineberger Comprehensive Cancer Center","biomarkers":" TNFRSF8","pipe":" | ","alterations":" TNFRSF8 expression","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • bendamustine • fludarabine IV • Belrapzo (bendamustine RTD) • TT11 • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 09/17/2019","start_date":" 09/17/2019","primary_txt":" Primary completion: 02/23/2028","primary_completion_date":" 02/23/2028","study_txt":" Completion: 08/01/2038","study_completion_date":" 08/01/2038","last_update_posted":"2024-04-23"},{"id":"d5dbb47e-aad4-4309-8d8b-fc01d9f10ce9","acronym":"LCCC 1606-ATL","url":"https://clinicaltrials.gov/study/NCT03602157","created_at":"2021-01-18T17:42:37.765Z","updated_at":"2024-07-02T16:35:08.204Z","phase":"Phase 1","brief_title":"Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL","source_id_and_acronym":"NCT03602157 - LCCC 1606-ATL","lead_sponsor":"UNC Lineberger Comprehensive Cancer Center","biomarkers":" TNFRSF8 • CCR4","pipe":" | ","alterations":" TNFRSF8 positive • TNFRSF8 expression","tags":["TNFRSF8 • CCR4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 positive • TNFRSF8 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bendamustine • fludarabine IV • TT11 • ATLCAR.CD30.CCR4 cells"],"overall_status":"Recruiting","enrollment":" Enrollment 59","initiation":"Initiation: 12/12/2018","start_date":" 12/12/2018","primary_txt":" Primary completion: 09/30/2026","primary_completion_date":" 09/30/2026","study_txt":" Completion: 09/30/2041","study_completion_date":" 09/30/2041","last_update_posted":"2024-04-23"},{"id":"c821b744-d6ee-407a-9a85-06ffcbe3a064","acronym":"CERTAIN","url":"https://clinicaltrials.gov/study/NCT04526834","created_at":"2021-01-18T21:40:44.865Z","updated_at":"2024-07-02T16:35:50.035Z","phase":"Phase 1","brief_title":"Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT04526834 - CERTAIN","lead_sponsor":"Tessa Therapeutics","biomarkers":" TNFRSF8","pipe":" | ","alterations":" TNFRSF8 positive","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TT11"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 21","initiation":"Initiation: 09/08/2021","start_date":" 09/08/2021","primary_txt":" Primary completion: 11/22/2022","primary_completion_date":" 11/22/2022","study_txt":" Completion: 03/01/2036","study_completion_date":" 03/01/2036","last_update_posted":"2023-04-20"},{"id":"5a039bc9-39b0-4a4e-8bec-0be78978180e","acronym":"CHARIOT","url":"https://clinicaltrials.gov/study/NCT04268706","created_at":"2021-01-18T20:44:27.947Z","updated_at":"2024-07-02T16:35:51.430Z","phase":"Phase 2","brief_title":"Phase 2 Study Evaluating Autologous CD30.CAR-T Cells in Patients With Relapsed/Refractory Hodgkin Lymphoma (CHARIOT)","source_id_and_acronym":"NCT04268706 - CHARIOT","lead_sponsor":"Tessa Therapeutics","biomarkers":" TNFRSF8","pipe":" | ","alterations":" TNFRSF8 positive","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fludarabine IV • Belrapzo (bendamustine RTD) • TT11"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 97","initiation":"Initiation: 02/01/2021","start_date":" 02/01/2021","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 03/01/2037","study_completion_date":" 03/01/2037","last_update_posted":"2023-04-05"},{"id":"3336dcde-07a1-4aaa-950a-9d3dd247d41a","acronym":"ACTION","url":"https://clinicaltrials.gov/study/NCT05352828","created_at":"2022-04-29T12:54:58.165Z","updated_at":"2025-02-25T14:16:54.400Z","phase":"Phase 1b","brief_title":"Autologous CD30.CAR-T in Combination With Nivolumab in cHL Patients After Failure of Frontline Therapy","source_id_and_acronym":"NCT05352828 - ACTION","lead_sponsor":"Tessa Therapeutics","biomarkers":" TNFRSF8","pipe":"","alterations":" ","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • fludarabine IV • TT11"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 07/25/2022","start_date":" 07/25/2022","primary_txt":" Primary completion: 12/15/2025","primary_completion_date":" 12/15/2025","study_txt":" Completion: 12/15/2037","study_completion_date":" 12/15/2037","last_update_posted":"2023-04-03"},{"id":"49925289-fb2e-43b6-8ef3-a1145df84116","acronym":"","url":"https://clinicaltrials.gov/study/NCT03914885","created_at":"2021-01-18T19:16:35.512Z","updated_at":"2024-07-02T16:36:19.889Z","phase":"","brief_title":"Compassionate Use Re-Infusion of ATLCAR.CD30","source_id_and_acronym":"NCT03914885","lead_sponsor":"UNC Lineberger Comprehensive Cancer Center","biomarkers":" TNFRSF8","pipe":"","alterations":" ","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bendamustine • fludarabine IV • Belrapzo (bendamustine RTD) • TT11"],"overall_status":"No Longer Available","enrollment":"","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2021-12-03"}]